Javier Rodriguez, CEO of DaVita, a network of kidney care services and outpatient dialysis centers, landed the No. 2 spot on nonprofit shareholder advocacy group As You Sow's list of "overpaid" healthcare CEOs.
The company reported Mr. Rodriguez's compensation at $73.4 million as of June 2021, which includes a five year equity grant. The equity grant is not guaranteed, but based on meeting specific benchmarks over time. The report calculated Mr. Rodriguez's CEO-to-worker pay ratio of 1,137-1. The DaVita network serves patients at 2,815 outpatient dialysis centers, in homes and in hospitals. It operates 339 outpatient dialysis centers in 10 countries worldwide.
Mr. Rodriguez took the helm in 2019 and last year grew the company to $978 million in net income, up from $774 million in 2020.
The only CEO ahead of Mr. Rodriguez on the list was Leonard Schleifer, MD, PhD, CEO of Regeneron Pharmaceuticals. Dr. Schleifer made $121.7 million with a CEO-to-worker pay ratio of 933-1. Mr. Rodriguez was ahead of Johnson & Johnson CEO Alex Gorsky, Centene CEO Michael Neidorff and Walgreens Boots Alliance CEO Stefano Pessina.
Samuel Hazen, CEO of HCA Healthcare, also made the list with $30.4 million in pay and a CEO-to-worker pay ratio of 556-1.
Last updated: 20 June 2022 at 4:50pm EST
The estimated Net Worth of Javier Rodriguez is at least $66.8 Million dollars as of 6 June 2022. Mr. Rodriguez owns over 79,909 units of DaVita Inc stock worth over $32,649,135 and over the last 15 years he sold DVA stock worth over $17,279,617. In addition, he makes $16,853,500 as Chief Executive Officer and Director at DaVita Inc.
Mr. Rodriguez DVA stock SEC Form 4 insiders trading
Javier has made over 34 trades of the DaVita Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 79,909 units of DVA stock worth $5,232,441 on 6 June 2022.
The largest trade he's ever made was exercising 280,000 units of DaVita Inc stock on 16 March 2018 worth over $16,503,200. On average, Javier trades about 37,337 units every 91 days since 2007. As of 6 June 2022 he still owns at least 381,059 units of DaVita Inc stock.
You can see the complete history of Mr. Rodriguez stock trades at the bottom of the page.
Javier J. Rodriguez serves as Chief Executive Officer, Director of the Company. From March 2014 until June 2019, he served as the CEO of DaVita Kidney Care. Since joining the Company in 1998, Mr. Rodriguez has served in a number of different capacities. From February 2012 to March 2014, he served as our President. From April 2006 through February 2012, he served as our Senior Vice President. Before that, from 2000 to 2006 he served as a Vice President of Operations and Payor Contracting. Mr. Rodriguez joined the Company in 1998 as a Director of Value Management. Prior to joining the Company, Mr. Rodriguez worked for Baxter Healthcare Corporation in Finance from 1995 to 1996. He also previously served as Director of Operations for CBS Marketing Inc. in Mexico City. Mr. Rodriguez provides extensive knowledge of our industry, business, regulatory environment and operations as well as significant executive leadership and management experience.
What is the salary of Javier Rodriguez?
As the Chief Executive Officer and Director of DaVita Inc, the total compensation of Javier Rodriguez at DaVita Inc is $16,853,500. There are no executives at DaVita Inc getting paid more.
Javier Rodriguez is 49, he's been the Chief Executive Officer and Director of DaVita Inc since 2019. There are 16 older and 3 younger executives at DaVita Inc. The oldest executive at DaVita Inc is John Nehra, 71, who is the Independent Director.
Javier's mailing address filed with the SEC is C/O DAVITA INC., 2000 16TH STREET, DENVER, CO, 80202.
Over the last 19 years, insiders at DaVita Inc have traded over $514,616,299 worth of DaVita Inc stock and bought 20,836,023 units worth $1,589,656,394 . The most active insiders traders include Hathaway Incbuffett Warren ..., R. Ted Weschler,, and Kent J Thiry. On average, DaVita Inc executives and independent directors trade stock every 12 days with the average trade being worth of $6,858,513. The most recent stock trade was executed by Michael David Staffieri on 23 June 2022, trading 20,000 units of DVA stock currently worth $1,554,000.
DaVita Inc. is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of December 31, 2020, DaVita served 204,200 patients at 2,816 outpatient dialysis centers in the United States. The company also operated 321 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere.
Complete history of Mr. Rodriguez stock trades at Gilead Sciences and DaVita Inc
DaVita Inc executives and other stock owners filed with the SEC include:
- Javier Rodriguez Chief Executive Officer, Director
- Joel Ackerman Chief Financial Officer, Treasurer
- Charles Berg Director
- Kathleen Waters Chief Legal Officer
- Javier J. Rodriguez CEO & Exec. Director
- LeAnne Zumwalt Group Vice President, Government Affairs
- Michael David Staffieri Chief Operating Officer of Kidney Care
- Joel Ackerman CFO & Treasurer
- Kathleen Alyce Waters Chief Legal and Public Affairs Officer
- James O. Hearty Chief Compliance Officer
- Barbara Desoer Independent Director
- Pascal Desroches Independent Director
- Pamela Arway Independent Chairman of the Board
- John Nehra Independent Director
- Paul Diaz Independent Director
- Phyllis Yale Independent Director
- Jim Gustafson Vice President - Investor Relations
- Paula Price Independent Director
- Shawn Guertin Director
- Kenny Gardner Chief People Officer - DaVita Kidney Care
- James Hearty Chief Compliance Officer
- John Winstel Chief Accounting Officer
- Kenneth Gardner Smith Chief People Officer
- Kenny Gardner Chief People Officer
- Atul Mathur Exec. VP of Global Operations
- Bill Myers VP of Marketing & Communications
- John D. Winstel Chief Accounting Officer
- Jeanine Marie Jiganti Chief Compliance Officer
- Peter T Grauer Director
- James K Hilger Vice President and Controller
- William L Roper Director
- Carol Anthony Davidson Director
- Roger Valine Director
- Joseph C Mello Chief Operations Officer
- Allen Nissenson Chief Medical Officer
- R. Ted Weschler,
- Hathaway Incbuffett Warren ...
- Robert J Margolis Co-Chairman of the Board
- Laura Mildenberger SVP & Chief People Officer
- Kim M Rivera VP, Gen. Counsel & Secretary
- Dennis Kogod President - West
- Garry E Menzel Senior Vice President, Finance
- David T Shapiro Chief Compliance Officer
- Charles J Mcallister Chief Medical Officer
- Steven J Udicious V.P., Sec. and Gen. Counsel
- Joseph Schohl VP, Secretary & Gen. Counsel
- Willard Woodson Jr Brittain Director
- Nancy Ann Deparle Director
- Mary Kowenhoven Vice President - Strategy
- Thomas O Usilton Group Vice President
- Patricia Jones Chief People Officer
- C Raymond Jr Larkin Director
- Christopher J Riopelle Chief Compliance Officer
- Thomas L Kelly Executive Vice President
- Luis Borgen Chief Financial Officer
- Georgina Randolph Senior Vice President
- Richard B Fontaine Director
- Mark G Harrison Chief Financial Officer
- Richard K Whitney Chief Financial Officer
- Richard C Vaughan Director
- Gary Beil Vice President and Controller
- Patrick A Broderick VP, Secretary & Gen. Counsel
- Lori Richardson Pelliccioni Cheif Compliance Officer
- Michele J Hooper Director
- Michael David Staffieri Chief Operating Officer, DKC
- Kent J Thiry Executive Chairman
- Gregory J. Moore Director